Lactobacillus gasseri APC 678 Reduces Shedding of the Pathogen Clostridium difficile in a Murine Model

is a common cause of health-care acquired diarrhea, resulting in a spectrum of disease from mild diarrhea to life-threatening illness. Sixty strains were screened for anti- activity using a co-culture method. Based on their ability to inhibit , APC 678 and DPC 6111 were selected for study in a murin...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in microbiology Vol. 10; p. 273
Main Authors Quigley, Lisa, Coakley, Mairéad, Alemayehu, Debebe, Rea, Mary C, Casey, Patrick G, O'Sullivan, Órla, Murphy, Eileen, Kiely, Barry, Cotter, Paul D, Hill, Colin, Ross, R Paul
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 20.02.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:is a common cause of health-care acquired diarrhea, resulting in a spectrum of disease from mild diarrhea to life-threatening illness. Sixty strains were screened for anti- activity using a co-culture method. Based on their ability to inhibit , APC 678 and DPC 6111 were selected for study in a murine model of infection. ATCC 33323, was included as a control. It was established that, relative to control mice not fed , feeding with APC 678 resulted in a significant reduction by day 7 (8-fold, = 0.017) of viable VPI 10463 in the feces of mice. In contrast, neither DPC 6111 nor ATCC 33323 significantly reduced fecal shedding. Sequencing of the cecal microbiota showed that in mice fed APC 678 there was a significant increase in bacterial diversity across a number of indices when compared to the control or other -fed groups. There was no significant change in the relative abundance of Firmicutes or Bacteroidetes in the group fed APC 678 relative to the control, while the groups fed DPC 6111 or ATCC 33323 showed a significant decrease in the relative abundance of Firmicutes ( = 0.002 and = 0.019, respectively) and a significant increase in Bacteroidetes ( = 0.002 and = 0.023, respectively). These results highlight the potential of APC 678 as a live therapeutic agent to target infection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors are joint first authors
Reviewed by: Casey Michelle Theriot, North Carolina State University, United States; M. Andrea Azcarate-Peril, The University of North Carolina at Chapel Hill, United States
Edited by: Meina Neumann-Schaal, German Collection of Microorganisms and Cell Cultures GmbH (DSMZ), Germany
This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
ISSN:1664-302X
1664-302X
DOI:10.3389/fmicb.2019.00273